AlphAIalphai — Financial news for AI agents
manilatimes.netJUL 143 min read$SILO

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

Silo Pharma (Nasdaq: SILO) said its wholly owned subsidiary QwikAgents was accepted into AMD’s AI Developer Program, gaining access to AMD Developer Cloud credits, tools, and training resources. QwikAgents is developing an enterprise AI agent platform with starter plans from $14 per month, targeting deployment, testing, optimization, benchmarking, and potential training of agent workloads.

Original reporting
manilatimes.net
Published Jul 14, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 14, 2026, 1:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform — source image
Source · manilatimes.net
Decision brief

The 30-second read

$SILONeutralLow
01

Why it matters

The announcement provides development resources (cloud credits, tools, training) intended to accelerate building, testing, optimizing, benchmarking, and potentially training AI agent workloads.

02

Market read

This is a partnership/program-access update that may support product development, but it lacks financial magnitude or near-term commercial commitments.

03

What to watch

Traders may want to watch for follow-on disclosures: customer deployments, unit economics, performance/benchmark results, or any AMD-related commercial commitments beyond credits.

Relevance 4/10Novelty 4/10Timing: today’s PR about QwikAgents joining AMD’s AI Developer Program

Background

Silo Pharma’s subsidiary QwikAgents is building a managed AI agent platform; the company now reports acceptance into AMD’s AI Developer Program.

Company-level read

Ticker impact

$SILONeutralMedium confidence
Context

Silo Pharma says its wholly owned subsidiary QwikAgents was accepted into AMD’s AI Developer Program, gaining AMD Developer Cloud credits and tools.

Expected impact

Likely limited near-term impact unless followed by measurable customer traction, pricing, or performance benchmarks.

Evidence & confidence

The release is a partnership/program access update with no financial terms, KPIs, or commitments; it supports development and testing rather than reporting results or contracts.

Market effects

Sector

Highlights growing cross-industry use of semiconductor vendor developer clouds for enterprise AI agent platforms.

Regional

No specific regional demand or regulatory linkage mentioned.

Global

AMD developer ecosystem expansion could marginally support broader enterprise AI agent development activity.

Counterpoint

What could challenge this read

Developer-program acceptance may be largely promotional and substitutable, with little incremental advantage versus other cloud/AI tooling options.

Key entities

  • company
    Silo Pharma

    Nasdaq-listed biopharma company whose subsidiary QwikAgents was accepted into AMD’s AI Developer Program.

  • subsidiary
    QwikAgents

    Wholly owned subsidiary developing a next-generation enterprise AI agent platform.

  • technology_partner
    Advanced Micro Devices

    Semiconductor company running the AMD AI Developer Program providing developer cloud credits and tools.

Read at source← All news

Related articles

JUL 10
$SILOMed

Silo Pharma Sinks on Stock Sale

Silo Pharma (NASDAQ: SILO) said it entered definitive agreements for a private placement at-the-market under NASDAQ rules to issue and sell 619,965 shares, or pre-funded warrants, plus Series A-3 and short-term Series A-4 warrants. Price was $6.452 per share, with $6.21 exercise price. Gross proceeds are about $4 million, up to $7.7 million if warrants are fully exercised.

baystreet.ca2 min
JUL 10
$SILOMedAI 8/10

Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Silo Pharma (Nasdaq: SILO) announced a private placement under Nasdaq at-the-market rules to issue 619,965 shares (or pre-funded warrants) at $6.452 per share, with Series A-3 and short-term Series A-4 warrants exercisable immediately. Gross proceeds are expected at about $4.0M, with up to about $7.7M more if warrants are fully exercised. Proceeds will fund working capital and general corporate purposes.

manilatimes.net4 min
JUL 10
$SILOMedAI 8/10

Silo Pharma, Inc.: Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Silo Pharma (Nasdaq: SILO) announced a private placement priced at-the-market under Nasdaq rules for 619,965 shares (or pre-funded warrants) plus Series A-3 and short-term Series A-4 warrants to buy up to 619,965 shares each. Price is $6.452 per share, with $6.21 warrant exercise. Gross proceeds are about $4M upfront, up to $7.7M if warrants are fully exercised in cash. Net proceeds for working capital and general corporate purposes.

finanznachrichten.de3 min
JUL 10
$METAHighAI 8/10

CCC Intelligent Solutions, Circle rise premarket; Silo Pharma, Fermi America fall By Investing.com

U.S. stock index futures were mixed premarket on Friday, with S&P 500 futures flat and Nasdaq 100 futures down 0.3% by 08:25 ET. CCC Intelligent Solutions rose 14.5% on a Reuters report it is exploring a sale with Morgan Stanley. Circle gained 7% after OCC approval for a digital currency bank. Meta rose 3.8% on a new AI model. Fermi America fell 14.6% after pricing $375m convertible notes, and Silo Pharma dropped 22% on an up to $11.7m ATM placement.

investing.com3 min
JUL 10
$SILOHighAI 9/10

Silo Pharma stock tumbles 22% on dilutive private placement By Investing.com

Silo Pharma (NASDAQ:SILO) shares dropped 22% after the company announced an up to $11.7 million private placement under Nasdaq rules. It plans to issue 619,965 shares plus Series A-3 and A-4 warrants for up to 619,965 shares each at $6.452 per share. Expected gross proceeds are about $4 million upfront, with up to about $7.7 million more if warrants are exercised.

investing.com4 min